Novel GKAPs for cGMP-dependent protein kinase type II: identification and functional significance by Boris M Hogema & Hugo R de Jonge
BioMed Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open AccessOral presentation
Novel GKAPs for cGMP-dependent protein kinase type II: 
identification and functional significance
Boris M Hogema* and Hugo R de Jonge
Address: Erasmus University Medical Center, Department of Biochemistry, Rotterdam, The Netherlands
Email: Boris M Hogema* - B.hogema@ErasmusMC.nl
* Corresponding author    
Many protein kinases are maintained in specific subcellu-
lar microenvironments by association to anchoring pro-
teins. Proper functioning of the cGMP-dependent protein
kinase II (cGK II) involves membrane targeting through
myristoylation. To determine whether additional binding
to anchoring proteins is also important for its targeting, in
analogy with G-kinase anchoring proteins (GKAPs) for
cGK I, and to identify potential new components of the
cGMP/cGK signalling pathway we performed a yeast two-
hybrid screen of novel cGK II binding partners. By screen-
ing a brain cDNA library using cGK II as a bait the inter-
mediate filament protein GFAP (glial fibrillary acidic
protein) was obtained as a positive clone. The interaction
was confirmed by overlay- and pull-down assays and by
immunoprecipitation. Interestingly, the highly homolo-
gous intermediate filament protein vimentin has previ-
ously been identified as a high affinity binding partner for
cGK Iα. We determined which domains are required for
the interaction and found, surprisingly, that the least con-
served N-terminal domain of the cGK's (aa 1–108 of
cGKII and 1–94 of cGK Iα) interacts with the most
strongly conserved core domain of the intermediate fila-
ments (aa 237–386 of GFAP). The physiological function
of the interaction is under current investigation.
We have previously identified the PDZ domain protein
NHERF-2 (E3KARP) as a low-affinity binding partner for
cGK II and NHERF-2 binding was shown to be required
for the cGMP-dependent inhibition of the sodium-proton
exchanger NHE3 in the PS120 fibroblast cell line [1]. To
determine whether NHERF-2 is also important for regula-
tion of ion transport in native intestinal tissue we deter-
mined cGMP-dependent inhibition of fluid transport in
NHERF-2 deficient mice. cGMP simultaneously activates
chloride secretion through the cystic fibrosis transmem-
brane conductance regulator (CFTR) chloride channel
and inhibits salt uptake through NHE3. Our results show
that whereas CFTR stimulation by 8-Br-cGMP was unal-
tered, the inhibition of salt- and fluid uptake in the small
intestine was strongly reduced in NHERF-2 deficient mice
suggesting that NHERF-2 functions as a GKAP for cGK II
in native tissue.
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